1Perdigón, G, Valdez, JC & Rachid, M (1998) Antitumour activity of yogurt: study of possible immune mechanisms. Journal of Dairy Research 65, 129–138.
2Isaacson, P (1982) Immunoperoxidase study of the secretory immunoglobulin system and lysozyme in normal and diseased gastric mucosa. Gut 23, 578–588.
3Prescott, SM & Fitzpatrick, FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470, M69–M78.
4Feghali, CA & Wright, TM (1997) Cytokines in acute and chronic inflammation. Front Biosci 2, d12–d26.
5Weitzman, SA & Gordon, LI (1990) Inflammation and cancer: role of phagocytegenerated oxidants in carcinogenesis. Blood 76, 655–663.
6Fulton, AM (1984) In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 44, 2416–2420.
7Lala, PK, Parhar, RS & Singh, P (1986) Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 99, 108–118.
8Reddy, BS, Maruyama, H & Kelloff, G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-nflammatory drug, during different stages of rat colon tumor development. Cancer Res 47, 5340–5346.
9de Moreno de LeBlanc, A, Valdéz, J & Perdigón, G (2004) Regulatory effect of yoghurt on intestinal inflammatory immune response. Eur J Inflamm 2(1), 21–61.
10Perdigón, G, de Moreno de LeBlanc, A, Valdez, JC & Rachid, M (2002) Role of yoghurt in the prevention of colon cancer. Eur J Clin Nutr 56, Suppl. 3, S65–S68.
11Bogdan, C, Rollinghoff, M & Diefenbach, A (2000) The role of nitric oxide in innate immunity. Immunol Rev 173, 17–26.
12Matar, C, LeBlanc, JG, Martin, L & Perdigón, G (2003) Biologically Active Peptides Released from Fermented Milk: Role and Functions. In Handbook of Fermented Functional Foods, pp. 177–201 [Farnworth, T, editor]. Boca Raton, FL, USA: CRC Press.
13LeBlanc, JG, Matar, C, Valdez, JC, LeBlanc, J & Perdigón, G (2002) Immunomodulatory effetcs of peptidic fractions issued from milk fermented with Lactobacillus helveticus. J Dairy Res 85, 2733–2742.
14Matar, C, Amiot, J, Savoie, L & Goulet, J (1996) The effect of milk fermentation by Lactobacillus helveticus on the release of peptides during in vitro digestion. J Dairy Sci 79, 971–979.
15Matar, C, Nadathur, SS, Bakalinsky, AT & Goulet, J (1997) Antimutagenic effects of milk fermented by Lactobacillus helveticus and its non-proteolytic variant. J Dairy Res 68, 601–609.
16Matar, C, Valdez, JC, Medina, M, Rachid, M & Perdigón, G (2001) Immunomodulating effects of milks fermented by Lactobacillus helveticus and its non-proteolytic variant. J Dairy Res 68, 601–609.
17de Moreno de LeBlanc, A, Matar, C, LeBlanc, N & Perdigón, G (2005) Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Research 7, 477–486.
18Purohit, A, Newman, SP & Reed, MJ (2002) The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4(2), 65–69.
19Urban, JL, Shepard, HM, Rothstein, JL & Sugarman, BJ (1986) Tumour necrosis factor: A potent effector molecule for tumour cell killing by activated macrophages. Proc Natl Acad Sci USA 83, 5233–5237.
20Ferrarini, M, Ferrero, E, Dagna, LPA & Zocchi, MR (2002) a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23, 14–18.
21Bingle, L, Brown, NJ & Lewis, CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196, 254–265.
22Brandtzaeg, P & Pabst, R (2004) Let's go mucosal: communication on slippery ground. Trends Immunol 25, 570–577.
23de Moreno de LeBlanc, A, Matar, C, Thériault, G & Perdigón, G (2005) Effects of milk fermented by Lactobacillus helveticus R389 on immune cells associated to mammary glands in normal and a breast cancer model. Immunobiology 210, 349–358.
24de Moreno de LeBlanc, A & Perdigón, G (2004) Yoghurt feeding inhibits promotion and progression of experimental colorectal cancer. Med Sci Monit 10(4), Br96–B104.